A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 882
- 试验地点
- 60
- 主要终点
- Number of Dual Efficacy Endpoint Events
研究概览
简要总结
A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).
详细描述
This study is being done to evaluate the efficacy of levosimendan compared with placebo in reducing the co-primary endpoints of 30-day composite of all-cause death or use of mechanical assist device (IABP, LVAD or ECMO) or the composite event rate of all-cause death, perioperative MI, need for dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on CPB.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan, or MRI within 60 days before surgery.
- •Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with mitral valve surgery, or 4) mitral valve surgery with or without other valves
- •Surgery will employ CPB pump
- •Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
排除标准
- •Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent on venous return.
- •Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours before surgery.
- •Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration).
- •Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m
- •Weight ≥ 170 kg.
- •Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study drug.
- •Heart rate ≥ 120 bpm, persistent for at least 10 minutes screening and unresponsive to treatment.
- •Hemoglobin < 80 g/L.
- •Serum potassium < 3.5 mmol/L and > 5.5 mmol/L at baseline.
- •A history of Torsades de Pointes.
- •Mechanical assist device (IABP, LVAD, ECMO) in the patient at the start of surgery or pre-planned to be inserted during surgery before coming off CPB.
- •Patients with aortal femoral occlusive disease that would prohibit use of IABP unless VAD or ECMO not available.
- •Liver dysfunction Child Pugh Class B or C
- •Patients having severely compromised immune function
- •Pregnant, suspected to be pregnant, or breast-feeding.
- •Received an experimental drug or used an experimental medical device in previous 30 days.
- •Known allergic reaction or sensitivity to Levosimendan or excipients.
- •Received commercial Levosimendan within 30 days before the planned start of study drug.
- •Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究组 & 干预措施
Levosimendan
levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
干预措施: Levosimendan (Drug)
Placebo
placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Dual Efficacy Endpoint Events
时间窗: 30 days
The all-cause death at 30 days or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) through Day 5
Number of Quad Efficacy Endpoint Events
时间窗: 30 days
Composite of all-cause death (at 30 days), or perioperative nonfatal MI \[CK-MB \>10xULN or \>100 ng/mL, CK-MB \>5xULN or 50 ng/mL with new Q wave (\>0.04 seconds wide in two contiguous leads) or new left bundle branch block)\] (through Day 5), or need for renal dialysis (through Day 30), or use of mechanical assist device (IABP, LVAD or ECMO) following the start of surgery for poor cardiac function despite inotropic support and adequate fluid replacement) (through Day 5)
次要结局
- Duration of Intensive Care Unit/Critical or Coronary Care Unit (ICU/CCU) (Days)(participants will be followed for during the participant's hospital stay up to 30 days)
- Incidence of Low Cardiac Output Syndrome (LCOS)(5 days)
- Postoperative Use of Secondary Inotrope(24 hours)